Stock PHVS PHARVARIS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Delayed Nasdaq
Other stock markets
 20:52:35 06/05/2024 BST 		5-day change 1st Jan Change
22.72 USD +0.53% Intraday chart for Pharvaris N.V. -3.11% -19.00%
04-15 Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating MT
04-12 Pharvaris Files Mixed Shelf MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pharvaris Narrows Q4 Net Loss; Hires New CFO
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Pharvaris Says FDA Lifts Clinical Hold on Application for Potential Treatment of Hereditary Angioedema Attacks
Correction: Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023
Koersalarm: aandeel Pharvaris blijft stijgen
Sector Update: Health Care Stocks Mixed Premarket Wednesday
Sector Update: Health Care
Pharvaris' Phase 2 Study of Deucrictibant Meets Primary Endpoint; Prices $300 Million Offering; Shares Jump 42% Pre-Bell
Top Premarket Gainers
Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
Pharvaris N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Pharvaris N : Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks (German) à link to Magerl
Pharvaris N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Pharvaris N.V. Announces Board Changes
Pharvaris Says US FDA Lifts Clinical Hold on IND Application for Hereditary Angioedema Treatment Candidate
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHVS Stock
  4. News Pharvaris N.V.
  5. Other languages